Crinetics Pharmaceuticals (CRNX) shares fell more than 8% in recent Thursday trading after the company said in a regulatory filing that Dana Pizzuti will step down as chief medical and development officer, effective Dec. 31.
Pizzuti will transition to the role of a strategic regulatory and development advisor.
She will provide transition services through March 31, 2026, and advisory services through March 30, 2028, according to the filing.
Price: 43.74, Change: -3.96, Percent Change: -8.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments